



INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



Guidelines For Treatment of Endocrine Disease During Pregnancy

Sumita Manhas*

College of Pharmacy Roorkee, Haridwar Uttarakhand -247667

Keywords:

Endocrine Diseases, Pregnancy Management, Guidelines, Multidisciplinary Approach, Pharmacological Considerations, Fetal and Neonatal Health, Maternal Outcomes

Corresponding Author-

Sumita Manhas

Email:

Sumitamanhas21@gmail.com

College of Pharmacy Roorkee
Haridwar Uttarakhand -247667

Volume 15, Issue 2, 2024

Received: 12 April 2024

Accepted: 15 April 2024

Published: 30 April 2024

DOI:

[10.69580/IJPPR.15.2.2024.11](https://doi.org/10.69580/IJPPR.15.2.2024.11)

[4-127](#)

ABSTRACT: Endocrine diseases during pregnancy present unique challenges due to physiological changes and potential impacts on maternal and fetal health. This review article provides comprehensive guidelines for managing endocrine disorders in pregnant individuals. It encompasses pre-conception counseling, monitoring, medication management, and risk assessment. Special focus is given to specific endocrine disorders such as gestational diabetes mellitus, thyroid disorders, hyperprolactinemia, adrenal disorders, pituitary disorders, gonadal disorders, parathyroid disorders, and pancreatic disorders. A multidisciplinary approach involving obstetricians, endocrinologists, and other specialists is emphasized to optimize care. Pharmacological considerations, lifestyle modifications, and non-pharmacological interventions are discussed in detail. Additionally, fetal and neonatal considerations, postpartum care, and avenues for future research are highlighted. By adhering to these guidelines, healthcare providers can effectively navigate the complexities of managing endocrine diseases during pregnancy, ultimately improving outcomes for both mother and child.

1. Introduction

The management of endocrine diseases during pregnancy is a critical aspect of maternal and fetal health, requiring a nuanced approach to ensure optimal outcomes. This review article delves into the guidelines for the treatment of endocrine diseases during pregnancy, focusing on the complexities and considerations that healthcare providers face in addressing these conditions.¹

Pregnancy introduces unique challenges in the management of endocrine diseases, such as goitre, gestational thyrotoxicosis, hypothyroidism, adrenal insufficiency, prolactinomas, and lymphocytic hypophysitis. Differentiating between conditions like Grave's disease and gestational thyrotoxicosis is crucial, with specific treatment protocols varying based on the stage of pregnancy. For instance, patients with adrenal insufficiency may require adjusted steroid doses during different trimesters, while

prolactinomas necessitate dopamine agonists as the primary treatment, with special monitoring for macroprolactinomas.²

The guidelines for treating endocrine diseases during pregnancy emphasize the importance of a multidisciplinary approach involving endocrinologists, obstetricians, and other specialists. Timely diagnosis and appropriate management are essential to mitigate adverse maternal and fetal outcomes associated with these conditions. The review article will delve into the current evidence and recommendations, shedding light on best practices and challenges in treating endocrine diseases during pregnancy.^{3,4}

By synthesizing the guidelines and evidence-based practices, this review aims to provide a comprehensive overview of the treatment strategies for endocrine diseases during pregnancy. It seeks to contribute to the enhancement of maternal and fetal health outcomes by offering insights into the complexities and advancements in managing endocrine conditions in pregnant individuals.⁵⁻⁷

2. Endocrine Diseases During Pregnancy

Endocrine diseases during pregnancy encompass various conditions that can impact both maternal and fetal health. These conditions include gestational thyrotoxicosis, Grave's disease, hypothyroidism, Addison's disease, Cushing's syndrome, prolactinomas, and lymphocytic hypophysitis. Management of these endocrinopathies is crucial to prevent adverse outcomes for both the mother and the fetus. Treatment strategies involve different approaches depending on the specific condition and the stage of pregnancy. For instance, propylthiouracil is used in early pregnancy for Grave's disease, while carbimazole is preferred later on. Patients with adrenal insufficiency may require higher steroid doses during certain trimesters. Dopamine agonists are commonly used to treat prolactinomas, with visual field monitoring recommended for

macroprolactinomas throughout pregnancy. Lymphocytic hypophysitis is increasingly recognized as a cause of hypopituitarism in late pregnancy and postpartum.^{8,9}

3. Guidelines for Management

3.1 Pre-conception Counseling

Pre-conception counseling is a critical aspect of planning a healthy pregnancy. It involves a comprehensive evaluation of a woman's health, including medical, reproductive, and family history, nutritional habits, drug exposures, and psychosocial profile. This evaluation helps identify potential risks and interventions that can optimize maternal health in preparation for pregnancy.¹⁰

Pre-conception counseling should begin during the adolescent years in the form of life skill development. For women planning a pregnancy in the near future, the preconception office visit should include a systematic enquiry into the medical, reproductive, and family histories, nutritional habits, drug exposures, and psychosocial profile. Women should be encouraged to book early for antenatal care, which should be person-centered with the implementation of effective clinical practices.¹¹

Folic acid supplementation should begin one month prior to conception, and women should be advised to lead a healthy lifestyle, abstaining from tobacco, alcohol, and recreational drugs. Achieving a healthy weight with optimal glycemic control is important in reducing both maternal and fetal risk.¹²

3.1 Medication management

Medication management is also crucial during pre-conception counseling. Women on medication for a medical disorder should be counseled on the risks and benefits of potential alternative medications, and medication use should be limited to conditions where the benefit outweighs the risk. Medical conditions may

require higher dosing during pregnancy due to increased renal and liver clearance.¹³

3.2 Monitoring and Assessment

Monitoring and assessment are ongoing processes during pre-conception counseling. Women should be screened for mental health disorders, and those at risk of pregnancy complications should be prioritized for preconception risk care. Topics to be discussed in preconception consultation include preconception care, prevention of congenital defects, and the identification and management of risk factors.¹⁴

3.3 Complications and Risk Management

Complications and risk management are critical components of pre-conception counseling. Poor developmental experience can increase the offspring's risk of non-communicable diseases, atopic conditions, cancers, and neurologic impairment. The benefits of intentionally preparing for pregnancy are supported by data indicating that unfavorable maternal and fetal outcomes can be reduced with optimal preconception care.¹⁵

4. Specific Endocrine Disorders

Endocrine disorders during pregnancy can have significant impacts on both maternal and fetal health. Here are some specific endocrine disorders and their management during pregnancy

a. Gestational Diabetes Mellitus (GDM) - GDM is the most prevalent endocrine disease during pregnancy, affecting up to 14% of pregnancies. It is characterized by glucose intolerance of variable degree with onset during pregnancy, usually during the second trimester. The diagnosis of GDM is based on the results of an oral glucose tolerance test (OGTT). Management of GDM includes lifestyle modifications, such as dietary changes and physical activity, and medical treatment, such as

insulin therapy or oral hypoglycemic agents, if needed.¹⁶

b. Thyroid Disorders - Thyroid disorders are common in pregnancy, with hypothyroidism affecting up to 3% of pregnancies and hyperthyroidism affecting up to 0.2% of pregnancies. Thyroid hormone is essential for fetal brain development, and maternal thyroid hormone levels should be monitored throughout pregnancy. Hypothyroidism is treated with levothyroxine replacement therapy, while hyperthyroidism is treated with antithyroid drugs, such as propylthiouracil or methimazole.¹⁷

c. Hyperprolactinemia - Hyperprolactinemia is characterized by elevated levels of prolactin, a hormone produced by the pituitary gland. It can cause menstrual irregularities, infertility, and galactorrhea. Dopamine agonists, such as bromocriptine or cabergoline, are the first-line treatment for hyperprolactinemia during pregnancy.¹⁸

d. Adrenal Disorders - Adrenal disorders, such as Addison's disease and Cushing's syndrome, can be challenging to diagnose and manage during pregnancy. Patients with adrenal insufficiency require higher replacement steroid doses during pregnancy, while those with Cushing's syndrome may require surgery or medical treatment.¹⁹

e. Pituitary Disorders - Pituitary disorders, such as prolactinomas and lymphocytic hypophysitis, can also affect pregnancy. Prolactinomas are commonly encountered in pregnancy, with dopamine agonists the treatment of choice. Women with macroprolactinomas should have visual field monitoring throughout pregnancy. Lymphocytic hypophysitis is increasingly recognized as a cause of hypopituitarism arising in late pregnancy and in the postpartum period.²⁰

f. Gonadal Disorders - Gonadal disorders, such as polycystic ovary syndrome (PCOS) and premature ovarian failure, can affect fertility and

pregnancy outcomes. Management of PCOS during pregnancy includes lifestyle modifications, such as diet and exercise, and medical treatment, such as metformin or insulin-sensitizing agents.²¹

g. Parathyroid Disorders - Parathyroid disorders, such as hyperparathyroidism, can affect calcium metabolism and bone health during pregnancy. Management of hyperparathyroidism during pregnancy includes medical treatment, such as calcimimetics or bisphosphonates, and surgical intervention if needed.²²

h. Pancreatic Disorders - Pancreatic disorders, such as acute pancreatitis, can occur during pregnancy and are associated with maternal and fetal morbidity. Management of acute pancreatitis during pregnancy includes supportive care, such as fluid and electrolyte replacement, and medical treatment, such as antibiotics or pain management.²³

Endocrine disorders during pregnancy require careful monitoring and management to ensure optimal maternal and fetal outcomes. Clinicians should be aware of the potential endocrine disorders that can occur during pregnancy and their optimal management.²⁴

5. Multidisciplinary Approach

The multidisciplinary approach in the management of endocrine diseases during pregnancy is fundamental to providing comprehensive care that addresses the complex needs of both the mother and the developing fetus. This approach involves collaboration among various healthcare professionals with expertise in obstetrics, endocrinology, maternal-fetal medicine, neonatology, nursing, and other relevant specialties.²⁵ Importance and components of the multidisciplinary approach.

5.1 Comprehensive Assessment

- Obstetricians, endocrinologists, and other specialists collaborate to conduct a thorough evaluation of the pregnant individual's medical history, current health status, and endocrine disorder(s).²⁶

- This assessment helps identify potential risks, complications, and the impact of the endocrine disorder on maternal and fetal health.²⁷

5.2 Individualized Care Planning

- A multidisciplinary team works together to develop personalized care plans tailored to the specific needs of each patient.²⁸

- Factors such as the type and severity of the endocrine disorder, maternal health status, gestational age, and fetal well-being are considered in formulating treatment strategies.²⁹

5.3 Coordinated Management

- Healthcare providers collaborate to coordinate the management of the endocrine disorder(s) with prenatal care, including monitoring, medication management, and lifestyle interventions.³⁰

- Regular communication among team members ensures that interventions are timely, appropriate, and aligned with the overall treatment goals.³¹

5.4 Risk Assessment and Mitigation

- The multidisciplinary team assesses potential risks associated with the endocrine disorder and its management during pregnancy.

- Strategies for mitigating risks, monitoring for complications, and addressing emergent situations are established collaboratively.³²

5.5 Education and Support

- Patients receive comprehensive education regarding their endocrine disorder, its implications for pregnancy, and the importance of adherence to treatment and follow-up care.

•Support services, such as counseling and resources for managing the psychosocial aspects of pregnancy with an endocrine disorder, are provided as needed.³³

5.6 Shared Decision-Making

•The multidisciplinary team engages in shared decision-making with the patient, empowering them to actively participate in their care.

•Patients are involved in discussions regarding treatment options, potential risks, and benefits, allowing them to make informed decisions that align with their values and preferences.³⁴

5.7 Continuity of Care

•Seamless communication and coordination among healthcare providers ensure continuity of care across various stages of pregnancy, delivery, and postpartum.

•Transition planning for postpartum follow-up and long-term management of the endocrine disorder is facilitated to support ongoing health and well-being.^{35,36}

Pharmacological considerations are pivotal in managing endocrine diseases during pregnancy, given the potential implications for both maternal and fetal health. Healthcare providers meticulously assess the risks and benefits of pharmacotherapy, carefully weighing the consequences of untreated endocrine disorders against the potential hazards of medication exposure during pregnancy. The selection of medications hinges on their efficacy in managing the specific endocrine disorder and their safety profile for maternal-fetal health. Adjustments to drug dosages may be necessary to accommodate physiological changes in pregnancy. Regular monitoring of maternal health parameters and fetal well-being is indispensable for evaluating treatment efficacy and detecting adverse effects.^{37,38}

Additionally, healthcare providers remain vigilant for any impact on fetal development and neonatal outcomes, ensuring thorough surveillance for signs of drug-related complications. Patient counseling plays a crucial role, in providing expectant mothers with comprehensive information about medication risks, alternative treatment options, and the importance of adherence to prescribed regimens. Interdisciplinary collaboration among healthcare professionals, including pharmacists, obstetricians, endocrinologists, and others, ensures coordinated management and holistic care throughout pregnancy. By navigating pharmacological considerations judiciously and tailoring treatment approaches to individual patient needs, healthcare providers can optimize outcomes for both mother and child while managing endocrine disorders during pregnancy.^{39,40}

7. Lifestyle Modifications and Non-pharmacological Interventions

Lifestyle modifications and non-pharmacological interventions are pivotal aspects of managing endocrine diseases during



Figure 1: Multidisciplinary approach in the management of endocrine diseases

6. Pharmacological considerations

pregnancy, aiming to optimize maternal health and mitigate potential risks to the developing fetus without relying solely on medication. These interventions encompass a range of strategies tailored to individual needs and the specific endocrine disorder being addressed. Guidance on nutrition plays a crucial role, particularly for conditions like gestational diabetes mellitus (GDM), where patients receive education on carbohydrate counting, meal planning, and portion control to regulate blood glucose levels effectively. Encouraging regular, moderate-intensity exercise is essential for controlling weight gain, improving insulin sensitivity, and promoting overall well-being.⁴¹

Patients are provided with recommendations on safe and suitable exercise routines, emphasizing activities such as walking, swimming, and prenatal yoga. Weight management is also emphasized to manage endocrine disorders and reduce the risk of complications, with guidance on healthy weight gain targets and lifestyle changes offered to address obesity or excessive weight gain. Pregnant individuals are encouraged to quit smoking and abstain from alcohol and illicit drugs, with healthcare providers offering counseling, support, and referral to cessation programs to assist with addiction cessation. Coping with stress and maintaining positive mental health are prioritized through relaxation techniques, mindfulness practices, and access to counseling services.⁴²

Additionally, promoting good sleep habits is essential for overall health and well-being, with guidance on improving sleep quality and managing common sleep disturbances associated with pregnancy provided. Finally, empowering patients with knowledge and skills to manage their condition(s) effectively is integral, focusing on medication adherence, self-monitoring, symptom recognition, and seeking timely medical assistance. By integrating these lifestyle modifications and non-pharmacological interventions into care plans, healthcare

providers can optimize maternal-fetal health and improve overall pregnancy outcomes.^{43,44}

8. Fetal and Neonatal Considerations

Fetal and neonatal considerations are paramount in the management of endocrine diseases during pregnancy, as the well-being of the developing fetus and newborn is intricately linked to maternal health and the management of maternal endocrine disorders. Aspects concerning fetal and neonatal considerations in this context:

8.1 Maternal Endocrine Disorder Control

Effective management of maternal endocrine disorders is essential for ensuring optimal fetal development and neonatal outcomes. Controlling blood glucose levels in conditions like gestational diabetes mellitus (GDM) or maintaining thyroid hormone levels within a normal range is critical to prevent adverse effects on fetal growth and development.⁴⁵

8.2 Fetal Growth and Development Monitoring

Regular monitoring of fetal growth and development is integral to detect any deviations from the expected trajectory and assess the impact of maternal endocrine disorders. Techniques such as ultrasound biometry and fetal Doppler studies enable healthcare providers to evaluate fetal growth parameters, amniotic fluid volume, and placental function.⁴⁶

8.3 Screening for Fetal Anomalies

Some endocrine disorders may increase the risk of fetal anomalies or developmental abnormalities. Screening tests such as fetal ultrasonography, amniocentesis, or genetic testing may be recommended to assess fetal anatomy and detect any congenital anomalies early in pregnancy.⁴⁷

8.4 Neonatal Complications

Infants born to mothers with poorly controlled endocrine disorders may be at increased risk of

neonatal complications, such as macrosomia (excessive birth weight), hypoglycemia, respiratory distress syndrome, and jaundice.

Healthcare providers remain vigilant for signs of neonatal complications, providing prompt intervention and supportive care as needed to optimize neonatal outcomes.⁴⁸

8.5 Neonatal Screening

Neonatal screening programs play a crucial role in identifying infants at risk of endocrine disorders or metabolic abnormalities shortly after birth. Screening tests may include assessments for congenital hypothyroidism, congenital adrenal hyperplasia, and other endocrine-related conditions, allowing for early detection and intervention.⁴¹

8.6 Breastfeeding Considerations

Breastfeeding is encouraged for most infants born to mothers with endocrine disorders, as it provides numerous health benefits and supports maternal-infant bonding. Healthcare providers offer guidance on breastfeeding techniques, nutritional support, and monitoring for any potential effects of maternal medications on breastfeeding infants.⁴⁹

8.7 Long-Term Follow-Up

Long-term follow-up of infants born to mothers with endocrine disorders is essential to monitor growth, development, and any potential late-onset complications or sequelae. Regular pediatric assessments and developmental screening help identify and address any emerging issues early in childhood.^{46,47}

9. Postpartum care

Postpartum care is a crucial phase in the management of endocrine diseases, ensuring the well-being of both the mother and the newborn following childbirth. Postpartum care in the context of endocrine disorders

9.1 Maternal Health Monitoring

- Continuous monitoring of maternal health is essential in the postpartum period, particularly for individuals with pre-existing endocrine disorders or those who developed gestational endocrine conditions during pregnancy.
- Healthcare providers assess maternal vital signs, symptoms, and laboratory parameters to monitor for any signs of endocrine dysfunction, complications, or postpartum mood disorders.⁵⁰

9.2 Medication Management

- Continuation or adjustment of medications used to manage endocrine disorders during pregnancy may be necessary in the postpartum period. Healthcare providers evaluate medication regimens based on maternal health status, breastfeeding considerations, and the resolution of pregnancy-related changes.
- Patients receive guidance on medication adherence, dosage adjustments, and potential interactions with breastfeeding, ensuring optimal management of endocrine disorders while minimizing risks to the mother and infant.⁵¹

9.3 Lactation Support

- Breastfeeding is encouraged for most mothers with endocrine disorders, as it provides numerous health benefits for both mother and child. Healthcare providers offer lactation support, guidance on breastfeeding techniques, and assistance with any breastfeeding-related challenges or concerns.
- For individuals with specific endocrine disorders or medications contraindicated during breastfeeding, alternative feeding options and nutritional support are discussed to ensure adequate infant nutrition.⁵²

9.4 Postpartum Depression Screening and Support

- Screening for postpartum depression and other mood disorders is integral in the postpartum period, especially for individuals with pre-existing endocrine disorders or a history of mental health issues.
- Healthcare providers offer screening tools, counseling, and referrals to mental health professionals or support groups for individuals experiencing postpartum depression or anxiety, promoting early intervention and support.⁵³

9.5 Resumption of Physical Activity

- Gradual resumption of physical activity is encouraged in the postpartum period, taking into account individual recovery, medical considerations, and clearance from healthcare providers.
- Healthcare providers guide postpartum exercise routines, pelvic floor rehabilitation, and strategies for promoting overall fitness and well-being.⁵⁴

9.6 Long-Term Follow-Up

- Long-term follow-up of individuals with endocrine disorders is essential to monitor for any recurrence or exacerbation of the condition, evaluate treatment response, and address any ongoing health concerns.
- Regular postpartum visits and assessments allow healthcare providers to track maternal health status, address any postpartum complications, and provide ongoing support and guidance.^{51,53}

10. Future directions and research needs

Future directions and research needs in managing endocrine diseases during pregnancy are critical for advancing knowledge and improving clinical outcomes. Firstly, understanding the long-term maternal and offspring outcomes of maternal endocrine disorders and their management is essential, including cardiovascular health, metabolic syndrome, and offspring neurodevelopmental outcomes.

Research into the safety and efficacy of pharmacological interventions used during pregnancy, such as medications for gestational diabetes mellitus and thyroid disorders, is paramount. Additionally, investigating personalized medicine approaches based on biomarkers, genetic factors, and clinical predictors can tailor treatment strategies for better outcomes. Lifestyle interventions, including diet, exercise, and stress management, need further study to optimize maternal glycemic control and overall pregnancy outcomes.^{55,56}

Moreover, addressing health disparities in the prevalence and management of endocrine diseases during pregnancy among different demographic groups is crucial. Research on interdisciplinary care models involving obstetricians, endocrinologists, and other specialists can enhance patient care and outcomes. By addressing these research needs, healthcare providers can improve clinical practice, optimize outcomes, and provide better care for pregnant individuals with endocrine disorders.⁵⁷

11. Conclusion

Future directions and research needs in managing endocrine diseases during pregnancy are critical for advancing knowledge and improving clinical outcomes. Firstly, understanding the long-term maternal and offspring outcomes of maternal endocrine disorders and their management is essential, including cardiovascular health, metabolic syndrome, and offspring neurodevelopmental outcomes. Research into the safety and efficacy of pharmacological interventions used during pregnancy, such as medications for gestational diabetes mellitus and thyroid disorders, is paramount. Additionally, investigating personalized medicine approaches based on biomarkers, genetic factors, and clinical predictors can tailor treatment strategies for

better outcomes. Lifestyle interventions, including diet, exercise, and stress management, need further study to optimize maternal glycemic control and overall pregnancy outcomes. Moreover, addressing health disparities in the prevalence and management of endocrine diseases during pregnancy among different demographic groups is crucial. Research on interdisciplinary care models involving obstetricians, endocrinologists, and other specialists can enhance patient care and outcomes. By addressing these research needs, healthcare providers can improve clinical practice, optimize outcomes, and provide better care for pregnant individuals with endocrine disorders.

References

1. *Management of Diabetes in Pregnancy*; 2017.
<http://www.moh.gov.my><http://www.acadmed.org.my><http://www.mems.my><http://www.perinata1-malaysia.org><http://www.fms-malaysia.org>
2. Lane MKM, Garedew M, Deary EC, et al. What to Expect When Expecting in Lab: A Review of Unique Risks and Resources for Pregnant Researchers in the Chemical Laboratory. *Chem Res Toxicol*. 2022;35(2):163-198. doi:10.1021/acs.chemrestox.1c00380
3. Calina D, Docea AO, Golokhvast KS, Sifakis S, Tsatsakis A, Makrigiannakis A. Management of endocrinopathies in pregnancy: A review of current evidence. *Int J Environ Res Public Health*. 2019;16(5). doi:10.3390/ijerph16050781
4. Silverstein J, Post AL, Chien ; A Jo, et al. Multidisciplinary Management of Cancer During Pregnancy. Published online 2020. doi:10.1200/OP.20
5. Standards of medical care in diabetes-2011. *Diabetes Care*. 2011;34(SUPPL.1). doi:10.2337/dc11-S011
6. Stern C, Schwarz S, Moser G, et al. Placental endocrine activity: Adaptation and disruption of maternal glucose metabolism in pregnancy and the influence of fetal sex. *Int J Mol Sci*. 2021;22(23). doi:10.3390/ijms222312722
7. 2013. *CMJ13-2-176-181-Williamson.Indd*.; 2013.
8. Questions and Answers Clinical Obstetrics The Fetus & Mother. In: *Clinical Obstetrics*. Wiley; 2007:1-168. doi:10.1002/9780470753293.anw1
9. Jee SB, Sawal A. Physiological Changes in Pregnant Women Due to Hormonal Changes. *Cureus*. Published online March 5, 2024. doi:10.7759/cureus.55544
10. *Dewhurst's Textbook of Obstetrics & Gynaecology*.; 2018.
11. Lassi ZS, Imam AM, Dean S V., Bhutta ZA. Preconception care: Screening and management of chronic disease and promoting psychological health. *Reprod Health*. 2014;11. doi:10.1186/1742-4755-11-S3-S5
12. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children. *Eur Thyroid J*. 2014;3(2):76-94. doi:10.1159/000362597
13. *Designed and Printed with Support from UNICEF*.; 2014.
14. *Management of Maternal Thyroid Disorders During Pregnancy*.; 2023.
15. Rajput R, Bajaj S, Ghosh S, et al. Thyroid disorders in pregnancy. *Thyroid*

- Research and Practice*. Published online February 15, 2023. doi:10.4103/trp.trp_17_22
16. GMEC-SCN-Endocrine-Disorders-Pregnancy-Guideline-v1. Published online 2018.
 17. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*. 2007;92(8 SUPPL.). doi:10.1210/jc.2007-0141
 18. *Endorsed Guideline: European Menopause and Andropause Society (EMAS) Position Statement on Testosterone.*; 2023. <https://www.ese-hormones.org/publications/directory/?Publication+Type=Guidelines>
 19. Hubalewska-Dydejczyk A, Trofimiuk-Müldner M. The development of guidelines for management of thyroid diseases in pregnancy – current status. *Thyroid Res*. 2015;8(Suppl 1):A11. doi:10.1186/1756-6614-8-s1-a11
 20. Wilson C. Endocrine disorders in pregnancy: Updated guidelines for the management of thyroid disorders in pregnancy. *Nat Rev Endocrinol*. 2012;8(11):624. doi:10.1038/nrendo.2012.156
 21. Endocrine Diseases in Pregnancy – GLOWM. Published online 2015.
 22. De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: An endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*. 2012;97(8):2543-2565. doi:10.1210/jc.2011-2803
 23. Ahn HY, Yi KH. Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum: 2023 Revised Korean Thyroid Association Guidelines. *J Bone Metab*. 2023;38(3):289-294. doi:10.3803/EnM.2023.1696
 24. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. *Thyroid*. 2017;27(3):315-389. doi:10.1089/thy.2016.0457
 25. Urgatz B, Poppe KG. Update on therapeutic use of levothyroxine for the management of hypothyroidism during pregnancy. *Endocr Connect*. 2024;13(3). doi:10.1530/EC-23-0420
 26. Hubalewska-Dydejczyk A, Trofimiuk-Müldner M, Ruchała M, et al. Thyroid diseases in pregnancy: Guidelines of the Polish Society of Endocrinology. *Endokrynol Pol*. 2021;72(5):425-488. doi:10.5603/EP.a2021.0089
 27. Paschou SA, Bletsas E, Papazisi M, et al. Screening and management of major endocrinopathies during pregnancy: an update. *Endocrine*. 2023;80(1):10-19. doi:10.1007/s12020-022-03237-y
 28. Charlotte J Frise and Catherine Williamson. *CMJ13-2-176-181-Williamson.Indd.*; 2013.
 29. Mahmud M, Mazza D. *Preconception Care of Women with Diabetes: A Review of Current Guideline Recommendations.*; 2010. <http://www.biomedcentral.com/1472-6874/10/5>
 30. Mahmud M, Mazza D. *Preconception Care of Women with Diabetes: A Review of Current Guideline Recommendations.*; 2010. <http://www.biomedcentral.com/1472-6874/10/5>
 31. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European Thyroid Association Guidelines for the Management of Subclinical

- Hypothyroidism in Pregnancy and in Children. *Eur Thyroid J.* 2014;3(2):76-94. doi:10.1159/000362597
32. Angela M. Leung et al. Endocrine Diseases in Pregnancy – GLOWM. Published online 2015.
33. Rajput R, Bajaj S, Ghosh S, et al. Thyroid disorders in pregnancy. *Thyroid Research and Practice.* Published online February 15, 2023. doi:10.4103/trp.trp_17_22
34. *Management of Maternal Thyroid Disorders During Pregnancy.*; 2023.
35. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism.* 2007;92(8 SUPPL.). doi:10.1210/jc.2007-0141
36. *Designed and Printed with Support from UNICEF.*; 2014.
37. Narayan B, Nelson-Piercy C. *S110-S116 S110.* Vol 16.; 2016.
38. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism.* 2015;100(2):342-362. doi:10.1210/jc.2014-3415
39. Grzeskowiak LE, Grieger JA, Clifton VL. Strategies towards improving pharmacological management of asthma during pregnancy. *Pharmacol Res.* 2018;130:85-92. doi:10.1016/j.phrs.2017.12.019
40. Khan I, Okosieme OE, Lazarus JH. Current challenges in the pharmacological management of thyroid dysfunction in pregnancy. *Expert Rev Clin Pharmacol.* 2017;10(1):97-109. doi:10.1080/17512433.2017.1253471
41. Gillett M, Royle P, Snaith A, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: A systematic review and economic evaluation. *Health Technol Assess (Rockv).* 2012;16(33):1-235. doi:10.3310/hta16330
42. SURYA PRAKASH BHATT TKLARG. ms07102. Published online 2007.
43. Verma N, Rastogi S, Chia YC, et al. Non-pharmacological management of hypertension. *J Clin Hypertens.* 2021;23(7):1275-1283. doi:10.1111/jch.14236
44. Hedayati SS, Elsayed EF, Reilly RF. Non-pharmacological aspects of blood pressure management: What are the data. *Kidney Int.* 2011;79(10):1061-1070. doi:10.1038/ki.2011.46
45. Ann Liebert M, Zimmerman D. *Fetal and Neonatal Hyperthyroidism.* Vol 9.; 1999.
46. Fowden AL. *Endocrine Regulation of Fetal Growth.* Vol 7.; 1995.
47. Zagrean AM. Maternal-Fetal and Neonatal Endocrinology: Physiology, Pathophysiology, and Clinical Management 1st Edition. *Acta Endocrinologica (Bucharest).* 2020;16(2):274-274. doi:10.4183/aeb.2020.274
48. Gluckman PD, Cutfield W, Hofman P, Hanson MA. The fetal, neonatal, and infant environments-the long-term consequences for disease risk. In: *Early Human Development.* Vol 81. Elsevier Ireland Ltd; 2005:51-59. doi:10.1016/j.earlhumdev.2004.10.003
49. Polin RA (Richard A, Abman SH, Rowitch DH, Benitz WE, Fox WW. *Fetal and Neonatal Physiology.*
50. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: An Endocrine Society clinical practice guideline. *Journal of*

- Clinical Endocrinology and Metabolism*. 2007;92(8 SUPPL.). doi:10.1210/jc.2007-0141
51. Pillay C, Clark K. Postpartum care of women with renal disease. *Best Pract Res Clin Obstet Gynaecol*. 2019;57:89-105. doi:10.1016/j.bpobgyn.2019.03.008
52. Rasmussen MLH, Poulsen GJ, Videbech P, Wohlfahrt J, Melbye M. Endocrine disease history and the risk of postpartum depression. *British Journal of Psychiatry*. 2023;222(3):119-124. doi:10.1192/bjp.2022.173
53. Martinez NG, Niznik CM, Yee LM. Optimizing postpartum care for the patient with gestational diabetes mellitus. *Am J Obstet Gynecol*. 2017;217(3):314-321. doi:10.1016/j.ajog.2017.04.033
54. Abubaker AOmar, Lam Din, Benson KJ. *Oral and Maxillofacial Surgery Secrets*.
55. Petca A, Dimcea DAM, Dumitraşcu MC, Şandru F, Mehedinţu C, Petca RC. Management of Hyperthyroidism during Pregnancy: A Systematic Literature Review. *J Clin Med*. 2023;12(5). doi:10.3390/jcm12051811
56. Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: Biological, clinical, and nonclinical factors - An endocrine society scientific statement. *Journal of Clinical Endocrinology and Metabolism*. 2012;97(9). doi:10.1210/jc.2012-2043
57. Zhou Q, Acharya G. Editorial: Placental Hormones and Pregnancy-Related Endocrine Disorders. *Front Endocrinol (Lausanne)*. 2022;13. doi:10.3389/fendo.2022.905829